National 863 Program's anti-tumor major innovative drug "Sida aniline" approved for global listing January 29, 2015 Source: Bio Valley China's anti-cancer original drug Sida aniline is the world's first approved subtype selective histone deacetylase oral inhibitor, and is the first original innovative drug authorized by China to be used in developed countries such as the United States. On January 27th, Shenzhen Microchip Biotechnology Co., Ltd. held a special release of the State 863 and the “Major New Drug Creationâ€. It marks a significant breakthrough in the integration of core technologies and capabilities of China's structure-based molecular design, target research, safety evaluation, clinical development and industrialization. It is a historic breakthrough in China's pharmaceutical industry. Prof. Ma Jun, chairman of the Chinese Society of Clinical Oncology and deputy director of the Asian Society of Clinical Oncology, said that about 1 in 10,000 people in China have malignant lymphoma. The first indication for citadel aniline is recurrent and refractory peripheral T. Cellular lymphoma, a clinical patient using this drug has been treated for long-term survival. Microcore has authorized the United States, Japan, Taiwan and other countries and regions to carry out clinical research on single tumors and other anti-tumor drugs against other solid tumors such as hematological tumors, non-small cell lung cancer and breast cancer. Lu Xianping, President and Chief Scientific Officer of Microchip Life Dr. Lu Xianping, President and Chief Scientific Officer of Shenzhen Microcore, introduced that Shenzhen Microcore Bio was founded in 2001 by the team of Dr. Returned to the United States, specializing in the development of original small molecule drugs. In the field of tumors, diabetes/metabolic diseases, and immune diseases, a number of original innovative drug product lines have been established from the laboratory to the clinical and industrial stage. At present, Microchip has applied for 67 global invention patents for compounds, of which 36 have been authorized. They will fully consider the national conditions, fulfill their corporate social responsibilities, provide support for low-income patients, provide charitable drugs, and reduce the financial burden of patients. Chen Kaixian, deputy chief of science and technology special technology of the country's "major new drug creation" Academician Chen Kaixian, the deputy chief of the National Science and Technology Major Project of “Major New Drug Creationâ€, believes that the successful research and development of Sida aniline is supported by the national innovation policy, and the venture capital investment, the joint return of the scientific team and the national clinical experts. Mechanism of action of sidaben Peripheral T-cell lymphoma (PTCL) is a group of heterogeneous lymphoblastic proliferative disorders, including approximately 18 pathological subtypes. The annual incidence of PTCL in China is about 60,000, and the annual prevalence rate is about 90/million, which can be attributed to rare diseases. Histone deacetylase (HDAC) is a family of important enzymes for epigenetic regulation. By developing HDAC inhibitors, tumors can be treated at the chromatin structure level. Sidabenamine is a Chinese-originated new oral subtype selective HDAC inhibitor with selective inhibition of HDAC1, 2, 3, and 10 subtypes. Sidabenamine inhibits the cell cycle of lymphoid and hematological tumors and induces tumor cell apoptosis by inhibiting specific HDAC subtypes and resulting chromatin remodeling and gene transcriptional regulation (ie, epigenetic regulation); Inducing and enhancing natural killer cell (NK) and antigen-specific cytotoxic T cell (CTL)-mediated tumor killing and inhibiting the inflammatory response of tumor pathology can not only directly contribute to circulating tumor cells and localization in T lymphoma The lesions produce a therapeutic effect and may also be applied to induce and enhance the overall regulatory activity of anti-tumor cellular immunity against other types of tumors. Fire Safety Water Barrier,Water Barrier,Water Filled Barriers,Garage Water Barrier Denilco Environmental technology(Suzhou)Co., Ltd. , https://www.wflood.com
